A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer

Trial Profile

A Phase 1 Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcer

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs PDA 002 (Primary)
  • Indications Diabetic foot; Peripheral arterial disorders
  • Focus Adverse reactions
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 22 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 19 Jul 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Sep 2016.
    • 23 Oct 2015 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top